Table 1. Demographic features of the study subjects.
| Control (n = 38) | Quiescent UC (n = 41) | Active UC (n = 96) | |
| Age, mean ± SD | 51.1±12.8 | 42.2±13.3b | 41.7±14.2c |
| Gender | 39.5% Male | 39.0% Male | 41.7% Male |
| Body Mass Index, mean ± SD | 28.6±4.8 | 28.0±6.4 | 26.7±5.9b |
| Smoking (% of total) | 5 (15.2%) | 1 (2.5%) | 5 (5.2%) |
| Any IBD Therapy (% of total) | 1 (2.6%) | 40 (97.6%)c | 89 (92.7%)c |
| 5-aminosalicylates (% of total) | 1 (2.6%)* | 33 (80.5%)c | 75 (78.1%)c |
| Corticosteroids (% of total) | 0 | 5 (12.2%) | 32 (33.3%)c,d |
| Immunomodulators (% of total) | 0 | 16 (39.0%)c | 28 (29.2%)c |
| Anti-TNF-α (% of total) | 0 | 14 (34.1%)c | 14 (14.6%)a,d |
a p<0.05, b p<0.01, c p<0.001 vs. control; d p<0.05 vs. quiescent UC. *This patient was started on therapy for presumed UC but with normal endoscopic evaluation was felt to have irritable bowel syndrome. Age and body mass index statistics were assessed by the Kruskal-Wallis test followed by the Mann-Whitney test. Categorical data were analyzed using the Pearson’s χ2 test. UC status determined by histologic activity.